Sarepta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT03532542
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Corporate Center Suite 540, Milwaukee, Wisconsin, United States
🇺🇸Neuromuscular Research Center, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03375255
- Locations
- 🇺🇸
Neuromuscular Research Center, Sacramento, California, United States
🇺🇸NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States
🇺🇸Rare Disease Research, LLC, Atlanta, Georgia, United States
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03375164
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03218995
- Locations
- 🇧🇪
Universitair ziekenhuis Gent, Gent, Belgium
🇫🇷Armand-Trousseau Hospital, Paris, France
🇮🇹Site Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02710500
- Locations
- 🇺🇸
Nationwide Children's Hosptial, Columbus, Ohio, United States
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02530905
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT02500381
- Locations
- 🇺🇸
Neuromuscular Research Center, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸David Geffen School of Medicine, UCLA, Los Angeles, California, United States
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02420379
- Locations
- 🇺🇸
Neuromuscular Research Center of Arizona, Phoenix, Arizona, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of California, Davis Medical Center, Sacramento, California, United States
Phase I/II Study of SRP-4053 in DMD Patients
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02310906
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇫🇷Institute de Myologie, Paris, France
🇮🇹Policlinico Universitario A Gemelli, Rome, Italy
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02286947
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States